Contents
Edit links
Tools
Actions
General
- What links here
- Related changes
- Upload file
- Special pages
- Permanent link
- Page information
- Cite this page
- Get shortened URL
- Download QR code
- Wikidata item
Print/export
- Download as PDF
- Printable version
Vaccine candidate against COVID-19
MigVax-101 is a COVID-19 vaccine candidate developed by Oravax Medical.[1][2][3]
References
- ^ Jaffe-Hoffman M (11 June 2021). "Israeli oral COVID-19 vaccine en route to clinical trials". The Jerusalem Post. Retrieved 2 November 2021.
- ^ Jaffe-Hoffman M (22 July 2021). "Israel to become first in world to test Oravax oral COVID-19 vaccine". The Jerusalem Post. Retrieved 2 November 2021.
- ^ "Oramed Announces Oravax's Oral COVID-19 Vaccine Has Received South African Approval to Initiate Phase 1 Trial". Cision PR News Wire. 29 October 2021. Retrieved 2 November 2021.
Scholia has a profile for MigVax-101 (Q110269796).
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|